Matrix Trust Co Invests $1.40 Million in Cencora, Inc. $COR

Key Points

• Matrix Trust Co purchased a new stake of 4,153 shares in Cencora (NYSE:COR) during Q4, valued at approximately $1.40 million.
• Institutional ownership is very high at 97.52%, and major funds like Vanguard, State Street and JPMorgan have recently increased their Cencora positions, signaling sizable institutional accumulation.
• Cencora has a market cap of $61.86 billion, beat EPS expectations last quarter with revenue up 5.5% year-over-year, and pays a quarterly dividend of $0.60 (annualized $2.40, ~0.8% yield).

Matrix Trust Co purchased a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,153 shares of the company's stock, valued at approximately $1,403,000.

A number of other hedge funds have also recently added to or reduced their stakes in COR. Vanguard Group Inc. lifted its stake in Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company's stock valued at $7,311,810,000 after acquiring an additional 916,506 shares during the last quarter. State Street Corp grew its position in Cencora by 9.3% in the third quarter. State Street Corp now owns 9,190,316 shares of the company's stock worth $2,872,249,000 after acquiring an additional 782,911 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Cencora by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company's stock worth $1,461,965,000 after purchasing an additional 821,098 shares during the last quarter. Boston Partners raised its holdings in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company's stock valued at $1,409,152,000 after purchasing an additional 89,506 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Cencora by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company's stock valued at $1,241,094,000 after purchasing an additional 115,278 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Price Performance

NYSE COR opened at $318.00 on Friday. Cencora, Inc. has a 1 year low of $267.40 and a 1 year high of $377.54. The company has a fifty day simple moving average of $352.91 and a 200 day simple moving average of $340.41. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The company has a market cap of $61.86 billion, a P/E ratio of 38.22, a P/E/G ratio of 1.51 and a beta of 0.68.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter last year, the firm posted $3.73 EPS. The business's quarterly revenue was up 5.5% on a year-over-year basis. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora's payout ratio is currently 28.85%.

Analyst Upgrades and Downgrades

COR has been the subject of a number of recent research reports. Morgan Stanley set a $380.00 price objective on shares of Cencora in a report on Tuesday, March 17th. Robert W. Baird set a $415.00 target price on Cencora in a report on Tuesday, January 13th. Leerink Partners reaffirmed an "outperform" rating on shares of Cencora in a research report on Tuesday, March 17th. Evercore reiterated an "outperform" rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Weiss Ratings raised Cencora from a "hold (c+)" rating to a "buy (b)" rating in a report on Thursday, February 5th. Twelve investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $403.17.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.38% of the company's stock.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.